ELAPRASE

Phase 3Protein / enzyme

Takeda

ELAPRASE is one of 54 small molecule programs targeting Cognitive impairment. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cognitive ImpairmentActive, not recruiting

Cognitive ImpairmentPhase 3

Active, not recruiting

Competition

Competitive Landscape

72 competitors in Cognitive Impairment

#DrugCompanyPhaseTrials

Aricept

Eisai

Approved

10 2

Exelon

Novartis

Approved

5 3

Ritalin

Novartis

Approved

3 4

Cymbalta

Jazz Pharmaceuticals

Approved

1 5

Aldactone

Pfizer

Approved

1 6

Avandia

Epidiolex

Glucophage

3 9

Lithobid

SSolvay Pharmaceuticals

Approved

2 10

Coumadin

AAbbott

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 2/3Active, not recruiting

Cognitive Impairment

NCT06031259

Clinical

Trials by Indication[1]

Mucopolysaccharidosis2 trials

A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)

Withdrawn· Takeda logo

Takeda·Phase 4·NCT05494593

A Study of Elaprase in Children and Adults With Hunter Syndrome (Mucopolysaccharidosis II) in India

Completed· Takeda logo

Takeda·Phase 4·NCT05058391·5 enrolled

Cognitive impairment2 trials

Extension Study of Idursulfase-IT Along With Elaprase in Children and Adults With Hunter Syndrome and Cognitive Impairment

Active, not recruiting· Takeda logo

Takeda·Phase 2/3·NCT06031259·6 enrolled

An Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment

Completed· Takeda logo

Takeda·Phase 1/2·NCT01506141·15 enrolled

Treatment1 trial

Study of Long Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Participants Who Have Completed Study HGT-HIT-094

Completed· Takeda logo

Takeda·Phase 2/3·NCT02412787·56 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for ELAPRASE. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ELAPRASE compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ELAPRASE. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 3[1]
Company: Takeda

ELAPRASE

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Mucopolysaccharidosis2 trials

Cognitive impairment2 trials

Treatment1 trial

References

Drug Info

Quick Facts

Related News